Clinical trials: Cancer of Brain and Nervous System
Osteosarcoma, Ewing's Sarcoma
Informed Consent in Pediatric Cancer Trials
Background: Informed consent is the process by which prospective participants in clinical trials learn about clinical research in order to decide whether they want to enroll in the study.
- Conditions
- Osteosarcoma, Ewing's Sarcoma, Neuroblastoma, Brain Tumors
- Trial name
- NCT00923650
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Fabry Disease, Cardiac Variant, Right Ventricular Hypertrophy
Myocardial Affectation in Patients With Fabry Disease Without Phenotypic Manifestation. Diagnostic Value of Biomarkers
The cardiac variant of the Fabry disease is a rare cardiomyopathy affecting 1/50000 individuals in general population. It is generally diagnosed in advanced stages of the disease, because it presents clinical features very…
- Trial name
- FAMY (NCT01442350)
- Volunteers
- 120 people
- Sponsor
- Francisco Marín Ortuño
Solid Malignancy Located in the Head and Neck, Cancer
Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis
Phase II study to evaluate the clinical potential of 68GaNOTA-anti-MMR-VHH2 for in vivo imaging of Macrophage Mannose Receptor (MMR)-expressing Macrophages by means of Positron Emission Tomography (PET) in patients with…
- Conditions
- Solid Malignancy Located in the Head and Neck, Cancer, Carotid Stenosis, Atherosclerosis of Artery
- Trial name
- MITRAS (NCT04758650)
- Testing
- 68GaNOTA-Anti-MMR-VHH2
- Where
- Belgium
- Volunteers
- 29 people
- Sponsor
- Universitair Ziekenhuis Brussel
Cushing Disease, ACTH-producing Pituitary Tumour
Evaluation of Positron Emission Tomography (PET) With [18F]FET for the Detection of ACTH-Secreting Corticotroph Pituitary Neuroendocrine Tumors.
Cushing's disease results from adrenocorticotropic hormone (ACTH) secretion by corticotroph pituitary neuroendocrine tumors (PitNETs).
- Trial name
- PiTFET (NCT07463625)
- Testing
- Data-only evaluation of [18F]FET PET, pituitary MRI, and biomarkers
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Hospices Civils de Lyon
Glioblastoma Multiforme of Brain, Anaplastic Astrocytoma of Brain
Trial of C134 in Patients With Recurrent GBM
The purpose of this project is to obtain safety information in small groups of individuals, scheduled to receive escalating doses of C134, a cancer killing virus (HSV-1) that has been genetically engineered to safely replicate…
- Conditions
- Glioblastoma Multiforme of Brain, Anaplastic Astrocytoma of Brain, Gliosarcoma of Brain
- Trial name
- C134-HSV-1 (NCT03657576)
- Testing
- C134
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Alabama at Birmingham
Diffuse Intrinsic Pontine Gliomas (DIPG), Progressive DIPG
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.
- Conditions
- Diffuse Intrinsic Pontine Gliomas (DIPG), Progressive DIPG, Refractory DIPG, Recurrent DIPG
- Trial name
- NCT06838676
- Testing
- ACT001
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 60 people
- Sponsor
- Nationwide Children's Hospital
Gliomas
Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents
The primary objective of this study is to evaluate the efficacy of a combined treatment with cilengitide and metronomic oral temozolomide as measured by 6 months overall survival (OS) after diagnosis of relapse or tumour…
- Trial name
- HGG-CilMetro (NCT01517776)
- Testing
- Cilengitide, Temozolomide
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- Martin-Luther-Universität Halle-Wittenberg
Relapsed Solid Tumors, Relapsed Leukemia
Pharmacokinetic Studies Participation Survey
Background: A pharmacokinetic (PK) study of a new drug involves taking several blood samples over a period of time from study participants to determine how the body handles the substance.
- Conditions
- Relapsed Solid Tumors, Relapsed Leukemia, Relapsed Brain Tumors
- Trial name
- NCT00923468
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, IDH-wildtype, Glioblastoma
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
Resection of glioblastoma in or near functional brain tissue is challenging because of the proximity of important structures to the tumor site.
- Conditions
- Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme of Brain, Astrocytoma, Malignant
- Trial name
- RECMAP (NCT06273176)
- Testing
- Awake mapping under local anesthesia, Asleep mapping under general anesthesia, Resection under general anesthesia without mapping
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 225 people
- Sponsor
- Erasmus Medical Center
Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Brain Stem Glioma
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
This phase I/II trial studies lapatinib to see how well it works in treating young patients with recurrent or refractory central nervous system (CNS) tumors.
- Conditions
- Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Ependymoma, Recurrent Childhood Giant Cell Glioblastoma
- Trial name
- NCT00095940
- Testing
- lapatinib ditosylate, therapeutic conventional surgery, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Glioblastoma, Newly Diagnosed MGMT Unmethylated Glioblastoma
OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma
This is a first-in-human Phase 1 two-part, open-label, multi-center, dose escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and maximum tolerated dose (MTD) of CT-179 in…
- Trial name
- OPAL (NCT07739017)
- Testing
- CT-179
- Where
- 6 sites in Australia
- Volunteers
- 54 people
- Sponsor
- Olivia Newton-John Cancer Research Institute
Metastatic Brain Tumor, Cerebral Metastases
Impact of Cognitive Rehab and Physical Activity on Cognition in Patients With Metastatic Brain Tumors Undergoing RT
To determine the feasibility of processes and instruments with an overarching purpose to guide the design of a larger study. To determine the feasibility of individuals with metastatic brain tumor(s) to engage in physical…
- Trial name
- NCT03096431
- Testing
- Physical Activity, Cognitive rehabilitation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Virginia Commonwealth University
GBM, DIPG Brain Tumor
Clinical Study of Allogeneic Vγ9Vδ2 T Cells in the Treatment of Brain Malignant Glioma
Primary brain malignant tumor has become the first lethal tumor in children and young adults, and the treatment is limited, and the prognosis of patients is poor.
- Conditions
- GBM, DIPG Brain Tumor, Medulloblastoma
- Trial name
- CSAγδTBMG (NCT06396481)
- Testing
- Vγ9Vδ2 T cell
- Where
- China
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Beijing Tiantan Hospital
Cancer Liver, Cancer Brain
Optimization of MRI for Radiation Therapy
Currently, appropriate patients undergo MRI imaging with immobilization and sequences optimized for diagnostic radiology purposes.
- Conditions
- Cancer Liver, Cancer Brain, Cancer Head &Neck, Cancer Pelvis
- Trial name
- NCT02045381
- Testing
- MRI Group
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- University of Michigan Rogel Cancer Center
Brain Tumor, Glioma
Gliogene: Brain Tumor Linkage Study
The goal of this research study is to investigate the role of genes that may point to a higher risk of developing a glioma. Researchers will use new gene mapping techniques to study how high-risk factors are passed on through a…
- Trial name
- NCT00418899
- Testing
- Questionnaire
- Where
- 15 sites in United States, Denmark and 4 more
- Volunteers
- 17,080 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Melanoma
Novel Ga68-PSMA PET/CT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Brain Metastases
This study aims to evaluate the diagnostic potential of 68-Gallium PSMA-PET/CT in stereotactic irradiated brain metastases from non-small cell lung cancer, melanoma and breast cancer.
- Conditions
- Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Melanoma, Brain Metastases From Breast Cancer
- Trial name
- NCT07511933
- Testing
- 86-Gallium PSMA PET/CT
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer, Traumatic Brain Injury
Purpose in Life Survey
At present, there is no empirical data that specifies the likely prevalence of purpose in life disruption among various clinical populations.
- Trial name
- PIL (NCT05790278)
- Testing
- Survey
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Mary Radomski
Cancer, Metastasis
Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
To determine the safety and efficacy of using the drug azeliragon combined with stereotactic radiosurgery. Specifically, to determine if this combination will lead to improved response in the brain (tumor shrinking in size) and…
- Conditions
- Cancer, Metastasis, Metastatic Cancer, Brain Metastases
- Trial name
- ADORATION (NCT05789589)
- Testing
- Azeliragon, Stereotactic radiosurgery, Corticosteroid
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Baptist Health South Florida
Solid Tumor, Hematological Malignancies
The Good Patient Study
Adolescents with cancer weigh multiple influences in medical decision-making, including their own best interest, the perceived wishes of family members, and the interpreted preferences of the health care team.
- Conditions
- Solid Tumor, Hematological Malignancies, Brain Tumor
- Trial name
- NCT02199548
- Testing
- Interview
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- St. Jude Children's Research Hospital
Gastric Cancer
Gastric Cancer Metastasized to the Central Nervous System (CNS)
Descriptive registry to investigate frequency of HER-2 positive gastric cancer involving CNS. Exploration of additional prognostic factors for brain involvement from gastric cancer.
- Trial name
- NCT01456455
- Where
- Switzerland
- Volunteers
- 150 people
- Sponsor
- University of Zurich
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.